Immunovant Inc (IMVT)
followers
·
Follow
| Sector: | FINANCE |
| Industry: | GENERAL FINANCE |
| SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| CEO: | Peter Salzmann |
| Employees: | 120 |
| Web site: | immunovant.com |
|
320 WEST 37TH STREET, NEW YORK, NY, 10018
917-580-3099
| |
-
Formally known as:
- IMMUNOVANT ORD SHS
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.
Please log in first to see chart